Lupin partners with TB Alliance to advance Telacebec for tuberculosis treatmentLupin partners with TB Alliance to advance Telacebec for tuberculosis treatment

Introduction

Leading pharmaceutical company partnered with TB Alliance to advance Telacebec for tuberculosis, leprosy, and buruli ulcer, supporting clinical development, manufacturing, regulatory compliance, and global patient access.

Share price movement of Lupin

On February 2, 2026, Lupin Ltd opened at ₹2,130.05, down 0.41% from its previous close of ₹2,138.65. The stock hit a high of ₹2,141.70 (0.14%) and a low of ₹2,077.55. By 2:36 PM, it traded at ₹2,106.00, down 1.53%, with a market capitalisation of ₹96,201.83 crore.

Lupin Partners with TB Alliance

Lupin Limited announced a collaboration with TB Alliance to advance Telacebec (Q203) for treating tuberculosis, leprosy, and buruli ulcer, targeting multiple mycobacterial diseases globally.

Under the agreement, TB Alliance will lead clinical development, while Lupin will support global manufacturing, regulatory compliance, and supply chain to ensure worldwide access to Telacebec for patients.

Stock performance of Lupin for Period of 1 week, 6 months, and 1 year

Lupin Ltd delivered a -0.09% return over the past week, rose 15.3% in the past six months, and gained 3.84% over the past one year.

Shareholding pattern of Lupin

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	46.90%	46.90%	46.90%
FII	21.50%	20.50%	21.30%
DII	25.60%	26.60%	25.60%
Public	6.00%	6.10%	6.30%

About Lupin

Lupin Limited (NSE: LUPIN) is a global pharmaceutical company offering branded, generic, and biotech products, with 15 manufacturing sites, seven research centers, and presence in over 100 markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs